Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 1999

View Archived Issues

AstraZeneca receives FDA approval of Rhinocort Aqua Nasal Spray

Adolor licenses ADL-8-2698 for treatment of constipation from Roberts

BMS and Gillette seek approval for Vaniqa in the U.S.

DuPont acquisition of CombiChem will enhance new drug discovery at the company

Candidate schizophrenia gene identified through Genset-Janssen collaboration

Ares-Serono initiates comparative study of Rebif and Avonex

Peptides for use in an HIV vaccine available for licensing from NIH

Dompe identifies lead tartronate derivative for development as antiosteopenic agent

ETA antagonist TBC-2576 is active in rat model of pulmonary hypertension

Meta-analysis establishes higher pregnancy rates with rFSH than with uFSH

Idec commences phase I/II study with IDEC-114 for treatment of psoriasis

Ares-Serono files for approval of new infertility treatment

Dual glucagon antagonists/cytokine inhibitors in the Merck pipeline

Potent antioxidant lipoic acid analogues with superior biological properties

ASBMR news: preclinical and clinical studies support efficacy, safety of Amgen's OPG

HMR's 2-fluoro-ketolides warrant further exploration for Rx of respiratory tract infections

PKC, cytokine inhibitors in development at AstraZeneca

Axonyx to develop AD diagnostic test based on Australian technology

Searle presents new series of potent and selective vitronectin receptor antagonists

Sch-55700 prevents a variety of eosinophilic responses in animal models

Neuroprotective agents with quinazoline structure patented by CoCensys

Agents for amyloidotic diseases designed at Pharmacia & Upjohn

Newly discovered complement inhibitor optioned by ZymoGenetics

Johnson & Johnson completes merger with Centocor

TAP to develop xanthine oxidase inhibitor from Teijin in North America

Microcide reports progress in efflux pump inhibitor programs at ICAAC

NCI supports clinical development of StressGen's lead product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...